Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Prostate Cancer

 

Immune Monitoring of Sipuleucel-T
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Investigator: Celestia S. Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01727154

Abiraterone With Or Without ABT-888 For Metastatic Castration-Resistant Prostate Cancer (7847)
A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT-888 For Patients With Metastatic Castration-Resistant Prostate Cancer

Investigator: Robert Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01576172

Phenelzine Sulfate and Docetaxel Post First-Line Docetaxel Therapy
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Currently Receiving and Progressing on Docetaxel Therapy

Investigator: Evan Yu, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01253642

Abiraterone Acetate for Metastatic, Castration Resistant Prostate Cancer
Open Label Pharmacodynamic Study of Abiraterone in the Treatment of Metastatic, Castration Resistant Prostate Cancer

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01508234

Abiraterone Acetate for Metastatic Hormone-Resistant Prostate Cancer (7639)
Open Label Pharmacodynamic Study of Abiraterone in the Treatment of Metastatic, Castration Resistant Prostate Cancer

Investigator: Robert Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01503229

Alpharadin® with Docetaxel for Castration-Resistant Prostate Cancer (20121484)
A PhaseI/IIa Study of Safety and Efficacy of Alpharadin® with Docetaxel in Patients with Bone Metastases from Castration-Resistant Prostate Cancer

Investigator: Tia Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01106352

OGX-011 for Metastatic Castrate Resistant Prostate Cancer (SYNERGY)
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer

Investigator: Celestia S. Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01188187

GTx-758 for Castration Resistant Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy

Investigator: Evan Yu, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01615120

Radiation Therapy vs. Androgen Deprivation
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy (RTOG 0534)

Investigator: George Laramore, MD, PhD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT00567580

BKM120 for Metastatic Castration-resistant Prostate Cancer
Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer

Investigator: Evan Yu, MD;   Conditions: Metastatic Prostate Cancer;    Status: Recruiting;   Study ID: NCT01385293

Degarelix Acetate Prior to Radiation Therapy (7846)
Degarelix Acetate Prior to Radiation Therapy

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01731912

PSK + Docetaxel for Metastatic Castration-resistant Prostate Cancer (7551)
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

Investigator: Celestia Higano, MD;   Conditions: Prostate Cancer;    Status: Closed;   Study ID: NCT01685489

Molecular correlates of sensitivity and resistance to therapy in prostate cancer (UW6932)
Molecular correlates of sensitivity and resistance to therapy in prostate cancer

Investigator: Robert Montgomery, MD;   Conditions: Metastatic Prostate Cancer;    Status: Recruiting;   Study ID: NCT01050504

PASS
Canary Prostate Active Surveillance Study

Investigator: Daniel W. Lin, MD;   Conditions: Prostatic Neoplasms;    Status: Recruiting;   Study ID: NCT00756665

SCORE (30824)
SCORE -- Assessment of Mood, Information Processing and Quality of Life in Prostate Cancer Survivors and Patients

Investigator: Monique Cherrier, PhD;   Conditions: Prostate Cancer;    Status: Recruiting

Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC (UW-6620)
A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer

Investigator: Tia Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT00488982

Diagnostic Imaging Study With 99mTc-MIP-1404 (20121505)
A Phase 2 Assessment of the Diagnostic Accuracy of Tc-MIP-1404 Imaging in Men with High-Risk Prostate Cancer Scheduled for Radical Prostatectomy and Extended Pelvic Lymph Node Dissection Compared to Histopathology

Investigator: William Ellis;   Conditions: Rectal Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT01667536

Provenge Registry for Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (PROCEED)

Investigator: Celestia Higano, MD;   Conditions: Advanced Prostate Cancer;    Status: Recruiting;   Study ID: NCT01306890

ARN-509 for Relapsed Hormone Sensitive Prostate Cancer (20130917)
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer

Investigator: Tia Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01790126

Biological Therapy w/wo Vaccine Therapy for Metastatic Hormone-Resistant Prostate Cancer (8037A)
A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer (mCRPC)

Investigator: Evan Yu, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01881867

PET Imaging as a Biomarker of Treatment Response for Prostate Cancer (8021)
PET Imaging as a Biomarker of Systemic Treatment Response for Men with Metastatic Castration-Resistant Prostate Cancer

Investigator: Evan Yu, MD;   Conditions: Genitourinary Cancer; Prostate Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT02169063

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer (7621)
Phase II Trial of Abiraterone Acetate Combined with Dutasteride with Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Signaling in Patients with Metastatic Castrate Resistant Prostate Cancer (CRPC)

Investigator: Robert Montgomery, MD;   Conditions: Prostate Cancer;    Status: Closed;   Study ID: NCT01393730

Enzalutamide Versus Bicalutamide in Men With Prostate Cancer (STRIVE)
A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy

Investigator: Celestia Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01664923

CFG920 for Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer

Investigator: Robert Montgomery, MD;   Conditions: Prostatic Neoplasms;    Status: Closed;   Study ID: NCT01647789

Galeterone for Castration Resistant Prostate Cancer (ARMOR2)
ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01709734

AZD8186 Ascending Dose Study
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient Advanced Solid Malignancies, With Expansion to Assess the Pharmacodynamic Activity of AZD8186 Within Prospectively-validated PTEN Deficient Tumours

Investigator: Celestia S. Higano, MD;   Conditions: Advanced Castrate-resistant Prostate Cancer (CRPC);, Squamous Non-Small Cell Lung Cancer (sqNSCLC);, Triple Negative Breast Cancer (TNBC);    Status: Recruiting;   Study ID: NCT01884285

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone (Taxynergy)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy

Investigator: Celestia S. Higano, MD;   Conditions: Metastatic Prostate Cancer;    Status: Closed;   Study ID: NCT01718353

HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01685268

MLN8237 for Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Investigator: Bruce Montgomery, MD;   Conditions: Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer;    Status: Recruiting;   Study ID: NCT01799278

ARN-509 for Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer

Investigator: Celestia Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01946204

Oral CFG920 for Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostatic Neoplasms;    Status: Closed;   Study ID: NCT01647789

Veliparib for Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib in Subjects With Solid Tumors

Investigator: Elizabeth Swisher, MD;   Conditions: High Grade Serous Ovarian Cancer, BRCA Mutated Breast Cancer;    Status: Closed;   Study ID: NCT01853306

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

Enzalutamide for Castrate-resistant Prostate Cancer
Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing

Investigator: ;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01942837